The Non-Profit Standard for Rare Disease Intelligence.

---

About the Consortium

Regal Intel serves as the non-profit dedicated to accelerating the search for cures and intercepting the diagnostic odyssey for rare**, complex, and high-velocity** diseases. We connect hospitals that treat patients with researchers developing new medicines. Utilizing a secure diagnostics framework and a strict "Code-to-Data" architecture, we enable hospitals to engage in this critical work without ever sending private medical records beyond their walls. This method safeguards privacy through no exfiltration while assisting pharmaceutical partners in creating safer, faster clinical trials—often by employing statistically exchangeable Synthetic Control Arms (SCAs) to minimize the necessity for unethical placebo groups. By linking these two spheres, Regal Intel ensures that new therapies can be approved more swiftly while maintaining strict protection of every patient's privacy.

Bridging Care and Cures through Sovereign Intelligence.

Regal Intel is a non-profit research consortium dedicated to a singular, urgent goal: shortening the journey from symptom to cure for patients with rare, complex, and high-velocity diseases. We function as the neutral bridge between health systems that cater to these patients and life sciences innovators who are working to find cures. Regal Intel was established to address this issue by transforming the medical research model.

Our Purpose: Connecting a Fragmented Ecosystem

For patients with rare, complex, and high-velocity diseases, the "Diagnostic Odyssey" can extend for five to seven years. During this time, patients are often misdiagnosed as "Metabolic Masqueraders," suffering irreversible physiological damage before the true pathology is identified. The clues necessary to diagnose these conditions—and the data essential for developing new therapies—are frequently scattered across thousands of disconnected hospitals. Traditionally, connecting these dots necessitated transferring patient data into central databases, which created privacy risks, "Data Deadlock," and legal obstacles.

Our Approach: Sovereign Intelligence

We specialize in deploying our sovereign diagnostics framework. Rather than requesting hospitals to disclose their sensitive records, we bring our research algorithms directly to the data source.

• For Health Systems: We implement our advanced diagnostics framework within your secure firewall. These tools analyze local records by calculating the continuous biological velocity of a patient's symptoms to generate actionable diagnosis intelligence, identifying undiagnosed risks and complex conditions years earlier. This enables you to enhance care, intercept catastrophic metabolic crises, and keep your Patient Health Information (PHI) entirely under your control.
• For Biotech & Pharma: We aggregate insights—not raw data—from this global network. We provide regulatory-grade Real-World Evidence (RWE) and biologically constrained "Synthetic Control Arms" that expedite clinical trials, reducing the cost and time needed to bring new orphan drugs to market.

Our Expertise

We extend beyond standard analytics. Our consortium is built upon deep expertise in regulatory science and solving the "Small N" data sparsity paradox. We specialize in validating digital biomarkers and delivering diagnosis intelligence for conditions that are "statistically invisible" to traditional methods, ensuring that even the rarest and fastest-mutating phenotypes produce robust, inspection-ready evidence.

Why We Are Different

As a 501(c)(3) non-profit fiduciary, we are not motivated by data monetization, but by the necessity for answers. We offer a trusted environment where hospitals can benchmark their care globally while remaining sovereign locally, and where pharmaceutical partners can access the high-fidelity evidence they need to save lives without compromising a single patient's privacy.

Global Answers. Local Privacy. One Consortium.